**Aseptic meningitis induced by intravenous immunoglobulins in a child with acute Epstein-Barr virus infection and thrombocytopenia**

Paolo Vassalini¹, Camilla Ajassa¹, Valentina Di Ruscio², Alessandra Morace², Jacopo Vergari¹, Cecilia Tosato¹, Giulia Savelloni¹, Claudio M. Mastroianni¹

¹Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy; ²Department of Pediatrics, Sapienza University of Rome, Italy

**SUMMARY**

Drug-induced aseptic meningitis (DIAM) represents a diagnostic challenge since clinical and cerebrospinal fluid (CSF) findings may be indistinguishable from a bacterial meningitis. Intravenous immunoglobulin (IVIg) are commonly used in a variety of diseases, including inflammatory and autoimmune disorders. Although usually well-tolerated, various adverse effects have been reported. DIAM is a serious neurological side effect of IVIg therapy: albeit rare (0.067% of all IVIg infusions), the condition represents an important diagnostic challenge and should be considered by physicians. Here we report a case of an aseptic meningitis induced by IVIg therapy in a child with acute Epstein-Barr virus (EBV) infection and thrombocytopenia.

**INTRODUCTION**

Intravenous immunoglobulin is a blood product used in a variety of diseases, such as immunodeficiency disorders, autoimmune and inflammatory diseases [1-3]. IgG is the main component of IVIg, but it also contains small amounts of others Ig classes (most IgA), albumin, sugars, salts and trace of non active polymers, which may contribute to tolerability difficulties [4]. Although IVIg therapy is considered safe, adverse effects do occur. Most of these are mild and alleviated after infusion withdrawal, but some side effects could be serious and life threatening, such as hemolytic anemia, anaphylaxis, thrombosis and renal failure [5]. Aseptic meningitis is a serious neurological side effect: although rare (0.067% of all infusions), this condition should be considered by physician, representing a diagnostic challenge because clinical and CSF findings may be indistinguishable from an infective meningitis [6]. Here we report a case of a child with EBV-related thrombocytopenia who developed aseptic meningitis following intravenous immunoglobulin infusion.

**CASE REPORT**

A 4-year-old previously healthy boy was admitted to Infectious Diseases Unit because of seven days of fever (T<sub>max</sub> 39°C) and sore throat. A diagnosis of acute EBV infection was made based on clinical symptoms and results of serological testing (VCA-IgM positive, VCA-IgG negative, EBNA-IgG negative). He also showed low platelet count (47,000/mmc) and therapy with betamethasone 0.2 mg/kg was started. After 4 days he was discharged in good general condition and a platelet count of 124,000/mm<sup>3</sup>.
Ten days after discharge the patient showed low platelet count (34,000/mmc) and EBV-DNA copies of 453/mL. He was admitted to our department starting treatment with IVIg 400 mg/kg. Six hours after the second dose of IVIg he developed fever (38.5°C), headache and vomiting. He was treated by the physician on duty with single dose of ceftriaxone 1 g/die.

Twelve hours after the beginning of symptoms, the physical examination revealed nuchal rigidity, and lumbar puncture (LP) was performed. CSF analysis showed an elevated white blood cell count of 2,993/mmc with a neutrophil predominance (84%), glucose (75 mg/dL) and proteins concentration (300 mg/L) were unremarkable. IVIg therapy was withdraw, while he continued ceftriaxone, and dexamethasone treatment was started. Film-array for neurotropic viruses and bacteria, gram stain and cultures of CSF were negative. Brain MR was unremarkable. Twenty-four hours after LP the clinical picture of meningitis completely resolved.

**DISCUSSION**

We report the first case of a child with Epstein-Barr virus (EBV)-related thrombocytopenia who developed aseptic meningitis following IVIg infusion. Due to temporal relation to IVIg administration and symptoms, this case can be considered as a DIAM IVIg-induced. This entity represents a diagnostic challenge since clinical and CSF findings may be indistinguishable from a bacterial meningitis; in particular this case, due to the administration of antibiotic therapy before LP, may lead to different interpretations.

Therapy with IVIg was introduced in 1982 for patients with antibody immunodeficiency; subsequently, it was developed for treatment of inflammatory diseases (thrombocytopenic purpura, Kawasaki disease, immunomediated neurologic disorders) and for treatment and prevention of some infectious disease including Tetanus, Hepatitis B, Varicella, CMV and EBV [3, 7-12]. Although considered safe, IVIg therapy adverse event do occur. Struff et al. reported among 1,705 immunodeficient patients given 15,548 infusions at the same IVIg product, only 0.6% had an adverse systemic reaction with an overall rate per infusion of 0.064% [13]. Higher rates of systemic reactions are reported in other groups, such as children, or patients affected by multiple myeloma, chronic inflammatory polyneuropathy, asthma and multiple sclerosis [14-18]. Adverse effect associated with IVIg can be local (at the infusion site) or systemic. Adverse systemic reactions are immediate (within 6 hours from infusion, 60% of reactions), delayed, occurring 6 hours to 1 week after infusion (40%), or late occurring greater than 1 week after infusion in less than 1% of reactions (Table 1).

Aseptic meningitis is a rare severe side effect of IVIg therapy occurring in 0.6-1% of patients [6,

### Table 1 - Drug related reactions to IVIg infusion (adapted from Stiehm [29]).

<table>
<thead>
<tr>
<th>Immediate reactions (within 6 hours)</th>
<th>Delayed reactions (6 hours to 1 week)</th>
<th>Late reactions (more than 1 week)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Anaphylactic reaction</td>
<td>• Aseptic meningitis</td>
<td>• Interference with immunodiagnosis&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>• Hypo/hypertension, tachycardia</td>
<td>• Hemolytic anemia</td>
<td>• Blood borne infectious diseases&lt;sup&gt;6&lt;/sup&gt;</td>
</tr>
<tr>
<td>• Fever, flushing</td>
<td>• Arthritis</td>
<td>• Interference with vaccine effectiveness</td>
</tr>
<tr>
<td>• Headache, arthralgia</td>
<td>• Hyponatriemia</td>
<td></td>
</tr>
<tr>
<td>• Anxiety, fatigue</td>
<td>• Neutropenia</td>
<td></td>
</tr>
<tr>
<td>• Nausea, vomiting</td>
<td>• Thrombosis/Embolism&lt;sup&gt;1&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>• Pain, swelling and erythema at infusion site</td>
<td>• Colitis&lt;sup&gt;2&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dermatologic complications&lt;sup&gt;3&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Pulmonary complications&lt;sup&gt;4&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Impaired renal functioning</td>
<td></td>
</tr>
</tbody>
</table>

<sup>1</sup>: arterial 80%, venous 20%.
<sup>2</sup>: Necrotizing enterocolitis in premature infants.
<sup>3</sup>: eczema, alopecia, erythema multiforme, dyshidrosis, baboon syndrome.
<sup>4</sup>: embolism, edema, pleural effusion, transfusion-related lung injury, leukocyte aggregation in lung.
<sup>5</sup>: particularly live virus.
<sup>6</sup>: Parvovirus B19, Prion diseases only theoretically, no cases of HCV transmission since 1996.
The onset is usually 6 to 24 hours after the infusion, and clinical features include headache (96%), fever (92%), meningeal signs (89%), nausea and vomiting (86%) [20, 21]. Cerebral spinal fluid analysis usually shows a pleocytosis of a hundred to several thousand cells per microliter (mean 300/mcL), with a polymorphonuclear predominance, elevated proteins level and normal glucose concentration [22, 23]. Neuroimaging is usually non-informative and bacterial culture and viral PCR are negative. It is usually self-limiting in few days after discontinuation of IVIg administration; treatment only consist analgesic therapy [24].

Table 2 - Characteristic of IVIg induced aseptic meningitis compared to main infectious meningitis.

<table>
<thead>
<tr>
<th></th>
<th>Appearance</th>
<th>Leukocytes/mcL and main type</th>
<th>Protein level mg/L</th>
<th>Glucose level</th>
<th>Microbiological and virological findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physiological condition</td>
<td>Clear</td>
<td>&lt;5 lymphocytes</td>
<td>80-450</td>
<td>2/3 of blood level</td>
<td>Sterile</td>
</tr>
<tr>
<td>Drug induced aseptic meningitis</td>
<td>Clear</td>
<td>100-2,000 neutrophils</td>
<td>Increased</td>
<td>2/3 of blood level</td>
<td>Sterile</td>
</tr>
<tr>
<td>Bacterial meningitis</td>
<td>Cloudy</td>
<td>500-10,000 neutrophils</td>
<td>Highly increased</td>
<td>Decreased</td>
<td>Culture/PCR positive</td>
</tr>
<tr>
<td>Viral meningitis</td>
<td>Clear</td>
<td>500-1000 lymphocytes</td>
<td>Normal or slightly increased</td>
<td>2/3 of blood level</td>
<td>PCR positive</td>
</tr>
</tbody>
</table>

Finally, we cannot exclude that EBV infection acts as trigger of immunological reaction to IVIg.

In summary, the initial presentation of IVIg-associated meningitis is indistinguishable from an infectious meningitis. Considering this is a very rare condition, DIAM IVIg-induced remains a great diagnostic challenge for physician. Further evidences are needed to evaluate the possible relation between EBV infection and IVIg reaction; in the meantime, we suggest being cautious when administering IVIg during EBV acute infection.

REFERENCES

Aseptic meningitis induced by intravenous immunoglobulins of intravenous gamma globulin in antibody immuno
[8] Imbach P., Barandun S., d’Apuzzo V., et al. High dose intravenous gammaglobulin for idiopathic throm-
[10] Fibl M.M. History of immunoglobulin replace-
meagalovirus immunoglobulin after thoracic transplan-
tation: an overview. Transplantation. 100 (Suppl. 3), S1-
S4, 2016.
ciency of antiviral therapy plus IVIG in a case of prima-
lin preparation: documentation of 15,548 administra-
[14] Singh-Grewal D., Kemp A., Wong M. A prospective study of the immediate and delayed adverse events fol-
[16] Donofrio P.D., Bril V., Dalakas M.C., et al. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneu-
cebo-controlled trial of high-dose intravenous immuno-
[19] Kemmotsu Y., Nakayama T., Matsuura H., Saji T. Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawas-
[21] Patel A., Potu K.C., Sturm T. A Case of IVIG in-
duced aseptic chemical meningitis. S. D. Med. 70, 119-
121, 2017.
[23] Kepa L., Oczko-Grzesik B., Stolarz W., Sobal-Szczygiel B. Drug-induced aseptic meningitis in sus-
ppected central nervous system infections. J. Clin. Neuro-
sci. 12, 562-564, 2005.
[25] Orbach H., Katz U., Sherer Y., Shoenfeld Y. Intrave-
nous immunoglobulin: adverse effects and safe admin-
[27] Jarius S., Eichhorn P., Albert M.H., et al. Intrave-
nous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic anti-
bodies and activate neutrophils in a TNFα-dependent and Fc-receptor-independent way. Blood. 109, 4376-
[28] Dashti-Khavidaki S., Aghamohammadi A., Farshad-
fi F., et al. Adverse reactions of prophylactic intrave-
nous immuno-globulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunode-
[29] Stiehm E.R. Adverse effects of human immuno-